Androstatriendione Steroids 633-35-2 Atd Muscle Building Steorids
Androstatriendione Steroids 633-35-2 Atd Muscle Building Steorids
Basic info.
Product name ATD
Other name: androsta-1,4,6-triene-3,17-dion(3,17 Keto-Etiochol-Triene); ANDROSTA-1,4,6-TRIENE-3,17-DIONE
CAS register number: 633-35-2
Molecular Formula: C19H22O2
Molecular weight: 282.37678
Melting Point: 164-165°C
Assay: 98%
Description:
Dutasteride (Avodart), is a dual 5-α reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). It is used to treat benign prostatic hyperplasia. It increases the risk of erectile dysfunction and decreased sexual desire.
Dutasteride (trademark name Avodart) is a dual 5-α reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). Used for benign prostatic hyperplasia; however, it increases the risk of erectile dysfunction and decreased sexual desire.Dutasteride useful for the symptoms of benign prostatic hyperplasia (BPH); colloquially known as an "enlarged prostate".In those who are being regularly screened 5-alpha-reductase inhibitor (finasteride and dutasteride) reduce the overall risk of being diagnosed with prostate cancer however there is insufficient data to determine if they have an effect on the risk of death and may increase the chance of more serious cases.
This class of medications increases rates of erectile dysfunction (with between 5% and 9% developing problems after starting their use). This is linked to lower quality of life and can cause stress in relationships. There is also an association with lowered sexual desire. It has been reported that these adverse sexual side effects may persist even after discontinuation of the drug.
The FDA has added a warning to dutasteride about an increased risk of high-grade prostate cancer. While the potential for positive, negative or neutral changes to the potential risk of developing prostate cancer with dutasteride has not been established, evidence has suggested it may temporarily reduce the growth and prevalence of benign prostate tumors, but could also mask the early detection of prostate cancer. The primary area for concern is for patients who may develop prostate cancer whilst taking dutasteride for benign prostatic hyperplasia, which in turn could delay diagnosis and early treatment of the prostate cancer, thereby potentially increasing the risk of these patients developing high-grade prostate cancer.
Applications:
Dutasteride, along with Finasteride is a 5-alpha-Reductase inhibitor which are a group of drugs with anti-androgenic properties which inhibit the conversion of testosterone into dihydrotestosterone (DHT). This is the same chemical found in Proscar and Propecia and is used in the treatment hyperplasia and androgenic alopecia. Because these drugs reduce levels of dihydrotestosterone (DHT) they are used to prevent and treat hairloss. It is most commonly used to treat enlarged prostate glands.
Dutasteride is useful for treating benign prostatic hyperplasia (BPH); colloquially known as an "enlarged prostate".
In those who are being regularly screened, 5-alpha-reductase inhibitors such as finasteride and dutasteride reduce the overall risk of being diagnosed with prostate cancer; however, there is insufficient data to determine if they have an effect on the risk of death and may increase the chance of more serious cases.
Dutasteride is marketed pharmaceutically as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost. For unknown reasons, early clinical trials for dutasteride were abruptly ceased in 2002, then continued later.
Dutasteride is a 5-alpha-reductase inhibitor, meaning it blocks the action of the 5a-reducatse enzymes, that are responsible for 5a-reducing (converting) testosterone into dihydrotestosterone (DHT) by the addition of a double hydrogen bond.
Dutasteride inhibits both isoforms of 5a-reductase, therefore preventing the conversion of testosterone into dihydrotestosterone. This makes Dutasteride a reasonable treatment for Male Pattern Baldness. Of course, when you convert less Testosterone into Dihydrotestosterone, you increase testosterone levels by default (less conversion).
Steroid Cycle
1, Front end loading-this cuts down on wasted time in the beginning of your cycle waiting for the doses to reach full therapeutic levels . The use of orals in the beginning of a cycle is a popular component of a cycle. While it is not a necessity, it too is a (different) type of front end load. For the advanced Bodybuilder, Dbol should be taken in the beginning of a cycle as well as loading the injectables since the anabolic response from Dbol is alleged to be by a different mechanism than most injectables. If one had to chose between a Dbol load and and injectable load, in most cases, the injectable load should be preferred over the Dbol load.
2, Injection frequency- This is crucial to obtaining even blood concentrations of androgens. Ideally, the more often injected, the better. An acceptable rule of thumb is "inject at half of the half life." For instance, if the half life of a steroid is 7 days, this should be injected at least twice weekly. For cycles that involve multiple injectables, the injections should be fractioned out and divided up based on the injectable with the shortest half life. For instance, if you were doing a test propionate and deca cycle, the old school way to do it would be to inject the prop EOD and the deca once a week. Both compounds should not be viewed as separate, but together with total androgen concentration taken into consideration. If you injected the deca only once a week, probably along with one of the propionate injections, that day will have a much larger spike on total blood androgen concentrations. Instead, the deca should be split up and taken with the propionate injections, EOD. This way there is no one day of the week that has a "spike" and even blood concentrations are maintained throughout the week.
3, Ending the cycle- Switching to shorter esters toward the end of a cycle makes perfect sense however not too many guys incorporate this practice- perhaps because of the lack of variety of drugs. The modern cycle should include replacing long ester injectables with shorter ones so that recovery time is made more efficient. The necessity of switching to shorter esters toward the end of a cycle depends on the type of drugs used. Longer esters such as deca and equipoise should be replaced with shorter acting versions of these compounds no later than four weeks before the end of a cycle. Medium length esters such as t-enanthate and cypionate should be replaced no later than three weeks before the end of a cycle. A couple examples of appropriate replacements are: trenbolone acetate and testosterone propionate. There is no need to "load" these compounds in the middle of a cycle since 1) they are already "fast acting" and 2) blood androgen concentrations are already high.
4, Recovery With the replacement of the faster acting injectables toward the end of a cycle, the "wasted" time between the end of a cycle and beginning of clomid therapy is reduced. For instance, if 100mg TA is used ED, clomid therapy may begin in as little as 5 days after the last shot. This tremendously improves time efficiency. Clomid Or post cycle therapy usually last for four weeks.
When the above recommendations are made, your cycle itself is made much more efficient and if recovery time is made more efficient as well, time "off" AAS may very well be reduced so that the overall efficiency of AAS use over time is tremendously improved.
Other supplier products
All supplier products
Same products
